CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 6, 2005, Pages 647-655

  Inomata, Shinichi ^a   Nagashima, Atsushi ^b   Itagaki, Fumio ^b   Homma, Masato ^b   Nishimura, Masuhiro ^b   Osaka, Yoshiko ^b   Okuyama, Kazuhiko ^b   Tanaka, Einosuke ^b   Nakamura, Takako ^b   Kohda, Yukinao ^b   Naito, Shinsaku ^b   Miyabe, Masayuki ^b   Toyooka, Hidenori ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DIAZEPAM; MESSENGER RNA;

ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; GENE IDENTIFICATION; GENERAL ANESTHESIA; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LYMPHOCYTE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL;

ACTINS; ADULT; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; FEMALE; GENOTYPE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RNA, MESSENGER; TIME FACTORS;

EID: 28844431530     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.020     Document Type: Article

References (32)

1. A.J.J. Wood Racial differences in the response to drugs - pointers to genetic differences N Engl J Med 344 2001 1393 1396
2. D.J. Greenblatt, B.L. Ehrenberg, J. Gunderman, A. Locniskar, J.M. Scavone, J.S. Harmatz Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo Clin Pharmacol Ther 45 1989 356 365
3. P.R. Schofield, M.G. Darlison, N. Fujita, D.R. Burt, F.A. Stephenson, H. Rodriguez Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family Nature 328 1987 221 227
4. S. Ono, T. Hatanaka, S. Miyazawa, M. Tsutsui, T. Aoyama, F.J. Gonzalez Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s role of CYP2B6, 2C19 and the 3A subfamily Xenobiotica 26 1996 1155 1166
5. T. Kubota, K. Chiba, T. Ishizaki Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population Clin Pharmacol Ther 60 1996 661 666
6. X.P. Qin, H.G. Xie, W. Wang, N. He, S.L. Huang, Z.H. Xu Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects Clin Pharmacol Ther 66 1999 642 646
7. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, F.P. Guengerich Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1994 414 423
8. T. Nakamoto, I. Hase, S. Imaoka, T. Hiroi, Y. Oda, A. Asada Quantitative RT-PCR for CYP3A4 nRNA in human peripheral lymphocytes induction of CYP3A4 in lymphocytes and in liver by rifampicin Pharmacogenetics 10 2000 571 575
9. F.J. Gonzalez, B.J. Schmid, M. Umeno, O.W. Mcbride, J.P. Hardwick, U.A. Meyer Human P450PCN1 sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase DNA 7 1988 79 86
10. T.R. Rebbeck, J.M. Jaffe, A.H. Walker, A.J. Wein, S.B. Malkowicz Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 90 1998 1225 1229
11. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
12. H. Hamzeiy, N. Vahdati-Mashhadian, H.J. Edwards, P.S. Goldfarb Mutation analysis of the human CYP3A4 gene 5' regulatory region population screening using non-radioactive SSCP Mutat Res 500 2002 103 110
13. H. Fukushima-Uesaka, Y. Saito, H. Watanabe, K. Shiseki, M. Saeki, T. Nakamura Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population Hum Mutat 23 2004 100
14. F. Sata, A. Sapone, G. Elizondo, P. Stocker, V.P. Miller, W. Zheng CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12 evidence for an allelic variant with altered catalytic activity Clin Pharmacol Ther 67 2000 48 56
15. K.P. Hsieh, Y.Y. Lin, C.L. Cheng, M.L. Lai, M.S. Lin, J.P. Siest Novel mutations of CYP3A4 in Chinese Drug Metab Dispos 29 2001 268 273
16. R. Eiselt, T.L. Domanski, A. Zibat, R. Mueller, E. Presecan-Siedel, E. Hustert Identification and functional characterization of eight CYP3A4 protein variants Pharmacogenetics 11 2001 447 458
17. J.K. Lamba, Y.S. Lin, K. Thummel, A. Daly, P.B. Watkins, S. Strom Common allelic variants of cytochrome P4503A4 and their prevalence in different populations Pharmacogenetics 12 2002 121 132
18. P. Bonnabry, J. Sievering, T. Leemann, P. Dayer Quantitative drug interactions prediction system (Q-DIPS). A dynamic computer-based method to assist in the choice of clinically relevant in vivo studies Clin Pharmacokinet 40 2001 631 640
19. M.K. Ang-Lee, J. Moss, C.S. Yuan Herbal medicines and perioperative care JAMA 286 2001 208 216
20. S.M.F. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, J.A. Goldstein The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 1994 15419 15422
21. S.M.F. de Morais, G.R. Wilkinson, J. Blaisdell, U.A. Meyer, K. Nakamura, J.A. Goldstein Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 1994 594 598
22. T.I. Edeki, J.A. Golstein, S.M.F. de Morais, L. Hajiloo, M. Butler, P. Chapdelaine Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans Pharmacogenetics 6 1996 357 360
23. E. Tanaka, M. Terada, S. Misawa, C. Wakasugi Simultaneous determination of twelve benzodiazepines in human serum using a new reversed-phase chromatographic column on a 2-μ porous microspherical silica gel J Chromatogr B Biomed Appl 682 1996 173 178
24. M. Nishimura, H. Yoshitsugu, S. Naito, I. Hiraoka Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR Yakugaku Zasshi 122 2002 339 361
25. M. Nishimura, H. Yaguti, H. Yoshitsugu, S. Naito, T. Satoh Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR Yakugaku Zasshi 123 2003 369 375
26. M. Nishimura, N. Ueda, S. Naito Effects of dimethyl sulfoxide on the gene induction of cytochrome P450 isoforms, UGT-dependent glucuronosyl transferase isoforms, and ABCB1 in primary culture of human hepatocytes Biol Pharm Bull 26 2003 1052 1056
27. I. Gashaw, J. Kirchheiner, M. Goldammer, S. Bauer, J. Seidemann, K. Zoller Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells correlation with alprazolam pharmacokinetics Clin Pharmacol Ther 74 2003 448 457
28. Uchida O. Palmacokinetics: a Palmware for pharmacokinetic simulation. Available from: URL:http://homepage1.nifty.com/o-uchida/palmacokinetics. Accessed Nov 4, 2005.
29. T. Katoh, K. Ikeda The effects of fentanyl on sevoflurane requirements for loss of consciousness and skin incision Anesthesiology 88 1998 18 24
30. T. Tateishi, Y. Krivoruk, Y.F. Ueng, A.J. Wood, F.P. Guengerich, M. Wood Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation Anesth Analg 82 1996 167 172
31. V.J. Palkama, P.J. Neuvonen, K.T. Olkkola The CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanyl Br J Anaesth 81 1998 598 600
32. N.P. Franks, W.R. Lieb Molecular and cellular mechanisms of general anaesthesia Nature 367 1994 607 614